Teva Pharmaceutical opened lower at $41.17, compared with its previous close of $41.47. In the last trading session, the stock traded between $41.17 and $42.59. It showed a sideways intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Teva Pharmaceutical is now worth
$ 477.92
giving a profit of
$ 377.92 (377.92%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 9 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.30 (+0.72%)
Day High
$42.59
Day Low
$41.17
Day Open
$41.17
Prev Close
$41.47
Volume
33,69,883
1W Return
3.93%
1M Return
4.89%
3M Return
20.42%
6M Return
18.06%
1Y Return
106.48%
Fundamentals
Market Cap ($ Mn)
48,674
PE Ratio
60.73
PB Ratio
5.48
PEG Ratio
-
ROE
21.09%
ROCE
7.77%
EPS (TTM)
$-0.49
Investment Returns
1 Week
3.93%
1 Month
4.89%
3 Months
20.42%
6 Months
18.06%
9 Months
26.31%
Financials
Quarterly
All values in $ Mn
3.9K
Mar 25
4.2K
Jun 25
4.5K
Sep 25
4.7K
Dec 25
4.0K
Mar 26
4.1K
Jun 26
Updates
20Oct
Teva, Sanofi report duvakitug efficacy in ulcerative colitis and Crohn's disease
Teva and Sanofi reported positive phase 2b long-term extension data for duvakitug. Drug maintained clinical remission and endoscopic improvement in UC and CD patients. Study included 130 patients randomized to 450 mg or 900 mg doses every four weeks. Safety profile remained consistent with the initial induction study results.
10 days ago
15Oct
Barclays raises Teva price target to $47, maintains Overweight rating
Barclays raised Teva Pharmaceutical Industries' price target from $42 to $47. The firm maintained an Overweight rating on the stock. Analyst Glen Santangelo led the revision in valuation.
15 days ago
2Oct
Teva presents ecopipam data showing 45.6% tic reduction at MDS 2026
Interim 18-month OLE study showed 45.6% mean reduction in tic severity scores. Post hoc analysis indicated 70% of participants saw meaningful tic reduction within 8 weeks. Concurrent psychiatric conditions did not negatively impact ecopipam’s efficacy or safety. Data supports ecopipam’s application currently under FDA Priority Review.
